Clinical trial NCT03071081: Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy Subjects
Official title: A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TOP1288 Oral Single Ascending and Multiple Doses in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Ulcerative Colitis
Lead sponsor: Topivert Pharma Ltd
Sponsor class: INDUSTRY
First posted: 2017-03-06
Enrollment: 37
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 3 dose groups (2 arms per dose group)
Primary purpose: TREATMENT

Brief summary: This study evaluates the safety and tolerability of TOP1288 oral single ascending and multiple doses in healthy subjects.


Eligibility criteria: Inclusion Criteria:

1. Subject is a healthy male, aged between 18 and 55 years of age (inclusive) at Screening.
2. Subject has a body mass index (BMI) of between 18.0 and 29.9 kg/m2 (inclusive), with a body weight of at least 50 kg at Screening.
3. Subject is in good physical and mental health in the opinion of the Investigator.
4. Subject has clinical laboratory test results within the reference ranges of the testing laboratory unless results outside the reference ranges are deemed not clinically significant by the Investigator at Screening and Day -1.
5. Subject has a supine blood pressure and pulse rate within the normal range after 5 minutes' rest (systolic blood pressure: 90 to 140 mmHg, diastolic blood pressure: 40 to 90 mmHg, pulse rate: 40 to 90 beats per minute) at Screening and Day -1.
6. Subjects must be willing to comply with the contraception restrictions of the protocol for this study.
7. Subject has regular bowel opening of usually 1 motion per day of normal consistency.

Exclusion Criteria:

1. Subject has participated in another study of an investigational medication (or a medical device) within the last 3 months or 5 half-lives of the investigational medication, whichever is longer, prior to the first day or dosing.
2. Subject has made a blood donation (\> 400 mL) or had a comparable blood loss (\> 350 mL) within the last 3 months prior to first administration of study drug.
3. Subject tests positive for human immunodeficiency virus (HIV)-1/2 antibodies, hepatitis B surface antigen, or hepatitis C antibodies at Screening.
4. Subject has a history of alcohol and/or drug abuse.
5. Subject has an alcohol consumption of more than 21 units of alcohol per week.
6. Subject tests positive for alcohol and/or drugs (urine tests) at Screening or admission.
7. Subject has received any prescription or non-prescription medications, including over-the-counter medications, nutraceuticals (e.g., St. John's Wort, ginseng, kava kava, Ginkgo biloba and melatonin), foods or beverages containing grapefruit and vitamin supplements within 14 days prior to admission (Day -1) or nutraceuticals containing caffeine- or xanthine-related substances within 72 hours prior to admission (Day -1). Foods or beverages containing Seville-type (sour) oranges, or poppy seeds are also excluded within this time period.
8. The subject has a history of daily consumption of 5 or more cups of coffee or tea.
9. Subject has a known hypersensitivity to any components of the study drug.
10. Subject has any history of any clinically significant acute or chronic condition affecting the colon and/or rectum and/or anus, including haemorrhoids and irritable bowel syndrome, sufficient to cause symptoms and/or that in the judgement of the PI and the Sponsor's study Physician/Medical Monitor would interfere with the subject's participation in the study.
11. Any findings on pre-dose endoscopy that in the PI's judgement would interfere with subject participation in the study.
12. Subject has acute or chronic condition affecting GI motility such as constipation or diarrhoea that would, in the judgement of the PI and the Sponsor's study Physician/Medical Monitor, interfere with the subject's participation in the study
13. Subject has cardiovascular or cerebrovascular disease, including hypertension, angina, ischaemic heart disease, transient ischaemic attacks, stroke and peripheral arterial disease sufficient to cause symptoms and/or require therapy to maintain stable status.
14. Subject has an active infection (e.g., sepsis, pneumonia, abscess) or has had a serious infection (resulting in hospitalisation or requiring parenteral antibiotic treatment) within 6 weeks prior to study drug administration.
15. Subject has a history of positive tuberculosis test or evidence of possible tuberculosis or latent tuberculosis infection at Screening (interferon gamma release assay testing) that cannot be attributed to a prior Bacillus Calmette-Guérin inoculation.
16. Subject has received live attenuated vaccination within 6 weeks prior to Screening or intends to have such a vaccination during the course of the study.
17. Subject has any of the following haematology values at Screening or Day -1:

    * Haemoglobin, \< 13 g/dL.
    * Absolute neutrophil count \< 1.5 x 109/L (\< 1500/μL).
18. Subject has a 12-lead electrocardiogram (ECG) with results considered to be potentially clinically significant, e.g., QTcF \> 450 ms, bundle branch block, evidence of myocardial ischaemia, at Screening or Day -1.
19. Subject has an abnormality in the ECG that, in the opinion of the Investigator, increases the risks associated with participating in the study.
20. Subject has renal or liver impairment at Screening or Day -1, defined as:

    * Serum creatinine level ≥ 135 μmol/L, or
    * Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥2 x upper limit of normal, or
    * Alkaline phosphate and/or bilirubin \> 1.5 x upper limit of normal (an isolated bilirubin 1.5 x upper limit of normal is acceptable if bilirubin is fractionated and direct bilirubin is \< 35%).
21. Subject has active neoplastic disease or history of any neoplastic disease within 5 years of Screening (except for basal or squamous cell carcinoma of the skin or carcinoma in situ that has been definitively treated with standard of care).
22. Subject has any other acute or chronic illness which, in the opinion of the Investigator or Sponsor's study Physician/Medical Monitor, could pose a threat or harm to the subject's participation in the study.
23. The subject has used nicotine-containing products (including, but not limited to, cigarettes, pipes, cigars, chewing tobacco, nicotine patch, or nicotine gum) within 2 weeks prior to admission to the study centre (Day -1).

Primary outcomes:
measure: Safety (AEs)
timeFrame: To 7 days after last dose
measure: Safety (ECGs)
timeFrame: To 7 days after last dose
measure: Safety (vital signs)
timeFrame: To 7 days after last dose
measure: Safety (clinical lab tests)
timeFrame: To 7 days after last dose
Secondary outcomes:
measure: Pharmacokinetic profile Cmax
timeFrame: 0-48 hours
measure: Pharmacokinetic profile AUC
timeFrame: 0-48 hours
measure: Pharmacokinetic profile AUC0-12h
timeFrame: 0-12 hours
measure: Pharmacokinetic profile AUC0-24h
timeFrame: 0-24 hours
measure: Pharmacokinetic profile AUC0-t
timeFrame: 0-48 hours
measure: Pharmacokinetic profile Racc
timeFrame: 0-48 hours
measure: Pharmacokinetic profile tmax
timeFrame: 0-48 hours
measure: Pharmacokinetic profile t½
timeFrame: 0-48 hours
measure: Pharmacokinetic profile λz
timeFrame: 0-48 hours
measure: Pharmacokinetic profile CL/F
timeFrame: 0-48 hours
measure: Pharmacokinetic profile Vz/F
timeFrame: 0-48 hours
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: PAREXEL Early Phase Clinical Unit
Study officials:
affiliation: Copenhagen Trial Unit, Center for Clinical Intervention Research
name: Muna Albayaty, MBChB, FFPM
role: PRINCIPAL_INVESTIGATOR
References: